The Yo-Yo Effect of GLP-1 Medications: Managing Weight Regain After Discontinuation

The rising popularity of GLP-1 receptor agonist medications like Wegovy and Mounjaro for weight loss is accompanied by a growing concern: what happens when you stop taking them? Even as these drugs can be highly effective for weight management, many individuals experience weight regain after discontinuation, often referred to as the “yo-yo effect.” This article explores the reasons behind this phenomenon and outlines strategies to minimize weight regain.

How GLP-1 Medications Work

Wegovy (semaglutide) and Mounjaro (tirzepatide) promote weight loss by mimicking the effects of glucagon-like peptide-1 (GLP-1), a hormone that regulates appetite and increases feelings of fullness. The World Health Organization (WHO) now recommends GLP-1 drugs as part of long-term treatment for obesity, acknowledging their potential for sustained weight management.

Why Weight Regain Occurs After Stopping GLP-1s

When GLP-1 medications are stopped, the hormonal effects that suppress appetite and promote satiety diminish. This can lead to an increase in appetite and a return to previous eating habits. Weight loss often results in a decrease in basal metabolic rate due to loss of muscle mass. If individuals revert to their old dietary patterns with a lower metabolism, weight regain is likely, potentially exceeding pre-treatment levels.

Research from Oxford University found that individuals who stopped taking GLP-1 medications regained an average of 0.4 kg per month, almost returning to their original weight within 1 year and 7 months. The rate of regain was four times faster than that observed when stopping traditional diet and exercise programs.

A 3-Step Strategy to Minimize Yo-Yo Effects

Experts emphasize that weight regain after discontinuing GLP-1 medications is a common occurrence, but its speed and extent can be mitigated through proactive lifestyle changes and a gradual reduction in dosage.

Step 1: Establish Weight Maintenance Habits

While appetite is suppressed by medications like Wegovy and Mounjaro, it’s crucial to develop sustainable habits that can be maintained independently. This includes:

• Consuming 2-3 meals per day, prioritizing protein (1.0-1.2g per kg of body weight) and vegetables.
• Limiting refined carbohydrates (flour, sugary foods) to 70% of usual intake.
• Practicing mindful eating – eating slowly when hungry and stopping when approximately 70-80% full.
• Engaging in strength training exercises (squats, planks, push-ups, lunges) 2-3 times per week.
• Incorporating aerobic exercise, such as walking, at least 2 times per week.

Maintaining muscle mass through exercise helps preserve basal metabolic rate, reducing the likelihood of significant weight gain after stopping medication.

Step 2: Gradual Dose Reduction

Upon reaching the target weight, avoid abruptly stopping the medication. Instead, consult with a healthcare provider to develop a strategy for slowly lowering the dose. This may involve maintaining a lower dose for 3-6 months to assess the body’s ability to adapt.

Step 3: Adherence Check 6 Months After Discontinuation

Monitor weight and waist circumference weekly. If an increase of 2-3 kg is observed, consider reducing carbohydrate intake and eliminating late-night snacks. To prevent psychological rebound, continue to allow small portions of favorite foods rather than complete restriction. Avoid immediately overindulging after stopping medication; instead, gradually increase food intake by 5-10% every two weeks while monitoring the body’s response.

GLP-1 Medication Dosage and Long-Term Employ

Both Wegovy and Mounjaro are administered via weekly injections, starting at low doses (Mounjaro 2.5mg/Wegovy 0.25mg) and gradually increasing at 4-week intervals to reach the target dose.

The question of long-term or lifelong use of GLP-1 medications is complex. Some experts view obesity as a chronic disease requiring ongoing management, similar to conditions like hypertension and diabetes. But, concerns regarding cost, gastrointestinal side effects, potential pancreatic, gallbladder, and thyroid issues, decreased muscle and bone mass, and nutritional deficiencies necessitate a cautious approach. The current consensus leans towards using the medication for an extended period, followed by dose reduction and individualized maintenance strategies, coupled with regular monitoring.